2-(3,5-Dimethylpiperazin-1-yl)ethan-1-amine | 356069-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(3,5-Dimethylpiperazin-1-yl)ethan-1-amine
• 英文别名: 2-(3,5-dimethylpiperazin-1-yl)ethanamine
• CAS: 356069-11-9
• 化学式: C₈H₁₉N₃
• 分子量: 157.26
• InChiKey: WBAUWDOMNXFSRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Pyrrole substituted 2-indolinone protein kinase inhibitors
  申请人：——

  公开号：US20020156292A1

  公开（公告）日：2002-10-24

  The present invention relates to pyrrole substituted 2 -indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use
  申请人：——

  公开号：US20030225147A1

  公开（公告）日：2003-12-04

  Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. 1 These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

  氨基噻唑化合物与单取代/双取代苯甲酰胺的结构由式(I)表示，并描述了它们的药学上可接受的盐、药学上可接受的前药、药学上活性代谢物以及所述代谢物的药学上可接受的盐。 这些药物调节和/或抑制细胞增殖和蛋白激酶活性，并可用作治疗恶性肿瘤和其他疾病的药物。
• Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
  申请人：Sugen, Inc.

  公开号：US20040186161A1

  公开（公告）日：2004-09-23

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，其调节蛋白激酶活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
  申请人：Ahmed Saleh

  公开号：US20060211678A1

  公开（公告）日：2006-09-21

  Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

  化合物式(I)所代表的化合物，或其立体异构体或药学上可接受的盐，是动物，包括人类体内至少两种Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK-1，GSK3β，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Ret和KDR激酶的抑制剂，用于治疗和/或预防各种疾病和病症，如癌症。
• AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS
  申请人：Kyoto University

  公开号：EP3246046A1

  公开（公告）日：2017-11-22

  The present invention provides a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), which contains one or more kinase inhibitors selected from the group consisting of an epithelial cell growth factor receptor (EGFR) inhibitor, a fibroblast growth factor receptor (FGFR) inhibitor, an Aurorakinase inhibitor, a protein kinase A (PKA) inhibitor, a protein kinase C (PKC) inhibitor, an MEK inhibitor, an Met inhibitor, a JNK inhibitor, a Syk inhibitor and a JAK inhibitor, a prostaglandin analogue and an estrogen receptor antagonist, or one or more kinase inhibitors selected from the group consisting of Tivozanib and an analog thereof, SB 216763, Cdk2 Inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL, AMODIAQUINE, SU9516, Sunitinib and an analog thereof, GSK-3 Inhibitor XIII, Bisindolylmaleimide I, HYDROQUINONE, FLUNISOLIDE, MGCD-265, Indirubin-3'-monoxime, HYDRASTINE (1R,9S), PIPERINE, BUTAMBEN, Axitinib and an analog thereof, APOMORPHINE, FENBUFEN, Bosutinib (SKI-606) and an analog thereof, a Wee1 Inhibitor, Cdk2 Inhibitor IV, NU6140, 3-hydroxybutyric acid, AT9283, Imatinib, Nilotinib, Rebastinib, and Bafetinib for the prophylaxis and/or treatment of ALS. Particularly, using a compound already on the market as a pharmaceutical product, a pharmaceutical product for the prophylaxis or treatment of ALS can be developed rapidly at a low cost.

  本发明提供了一种肌萎缩性脊髓侧索硬化症（ALS）的预防和/或治疗剂，它含有一种或多种激酶抑制剂，这些激酶抑制剂选自由上皮细胞生长因子受体（EGFR）抑制剂、成纤维细胞生长因子受体（FGFR）抑制剂、Aurorakinase抑制剂、蛋白激酶A（PKA）抑制剂、蛋白激酶C（PKC）抑制剂组成的组、成纤维细胞生长因子受体 (FGFR) 抑制剂、Aurorakinase 抑制剂、蛋白激酶 A (PKA) 抑制剂、蛋白激酶 C (PKC) 抑制剂、MEK 抑制剂、Met 抑制剂、JNK 抑制剂、Syk 抑制剂和 JAK 抑制剂、前列腺素类似物和雌激素受体拮抗剂、或一种或多种激酶抑制剂，这些激酶抑制剂选自以下组别：Tivozanib 及其类似物、SB 216763、Cdk2 抑制剂 II、BUDESONIDE、RIBOFLAVIN、alpha-TOCHOPHEROL、AMODIAQUINE、SU9516、Sunitinib 及其类似物、GSK-3 抑制剂 XIII、Bisindolylmaleimide I、HYDROQUINONE、FLUNISOLIDE、MGCD-265、吲哚啉-3'-monoxime、氢化胱氨酸 (1R,9S)、哌啶、布坦本、阿希替尼及其类似物、阿朴磷、芬布芬、博苏替尼 (SKI-606) 及其类似物、Wee1抑制剂、Cdk2抑制剂IV、NU6140、3-羟基丁酸、AT9283、伊马替尼、尼洛替尼、雷巴替尼和巴非替尼，用于预防和/或治疗ALS。特别是，利用已作为药品上市的化合物，可以低成本快速开发出预防或治疗 ALS 的药品。